Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study.

Renzapride replaces specific binding of [H³] GR 113808 (a selective 5-HT receptor antagonist) to cloned human 5-HT₄ receptors with a K_i value of 115 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Renzapride (BRL 24924) (100 µg i.v.) results in a partial reverse of both the delayed solid and liquid meals emptying.
Renzapride (BRL 24924) (0.5-1 mg/kg) significantly increases the rate of emptying of a ⁵¹Cr-labeled liquid meal from the murine stomach^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Renzapride (BRL 24924) (100 µg i.v.) results in a partial reverse of both the delayed solid and liquid meals emptying.
Renzapride (BRL 24924) (0.5-1 mg/kg) significantly increases the rate of emptying of a ⁵¹Cr-labeled liquid meal from the murine stomach^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Camilleri M, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2(10):895-904.  [Content Brief]

  . Scarpellini E, et al. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17(11):1663-1670.  [Content Brief]

  . Nagakura Y, et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999;39(5):375-382.  [Content Brief]

  [4]. Mawe GM, et al. Blockade of 5-HT-mediated enteric slow EPSPs by BRL 24924: gastrokinetic effects. Am J Physiol. 1989;257(3 Pt 1):G386-G396.  [Content Brief]